Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection

NCT05857163 is registered in ClinicalTrials.gov with TenNor Therapeutics (Suzhou) Limited as lead sponsor.

NCT NCT05857163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection
Lead sponsor
TenNor Therapeutics (Suzhou) Limited
Phase
Phase 3
Overall status
Completed
Start date
May 18, 2023
Completion date
March 26, 2024
Enrollment
700 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

h.pylori infection